WELCOME TO THE

SARS-CoV-2/COVID19

What does it mean to be a COVID-19 Long-Hauler?

By vgn1 | January 4, 2021

What does it mean to be a COVID-19 Long-Hauler? Some of the serious aspects of COVID-19 are long-term symptoms that persist for a significant period after SARS-CoV-2 infection and acute symptoms have apparently resolved. People experiencing these conditions have been called “long-haulers” and are a consequential proportion of those infected with SARS-CoV-2. Particularly, many patients…

ROBERT GALLO OF THE UM SCHOOL OF MEDICINE INSTITUTE OF HUMAN VIROLOGY AND GLOBAL VIRUS NETWORK AWARDED TOP LIFE SCIENCES AND MEDICINE PRIZE FROM CHINA

By vgn1 | December 21, 2020

Baltimore, Maryland, USA, December 21, 2020: Robert C. Gallo, MD, The Homer & Martha Gudelsky Distinguished Professor in Medicine, co-founder and director of the Institute Human Virology at the University of Maryland School of Medicine and co-founder and international scientific advisor of the Global Virus Network, was awarded the “VCANBIO Award for Biosciences and Medicine,”…

GLOBAL VIRUS NETWORK COMMENDS THE PHARMACEUTICAL INDUSTRY FOR UNPRECEDENTED COVID-19 VACCINE ADVANCES

By vgn1 | December 16, 2020

Recommends Large-scale Vaccination To Thwart The Pandemic Baltimore, Maryland, USA, December 16, 2020:  The Global Virus Network (GVN), a coalition comprised of the world’s preeminent human and animal virologists from 59 Centers of Excellence and 10 Affiliates in 33 countries, working collaboratively in the preparedness, defense and first research response to emerging, exiting and unidentified…

Interferon Antagonism of SARS-CoV-2

By vgn1 | December 7, 2020

It has become clear that the type 1 interferon responses to SARS-CoV-2 have a great deal to do with the outcome of infection. Patients with benign courses of infection yield high levels of expression of interferon-α (IFNα), while critical cases of COVID-19 show low levels of its expression. Paradoxically, in severe disease, expression of INF…

Progress in the Treatments of COVID-19

By vgn1 | November 25, 2020

Since the beginning of the COVID-19 pandemic, extensive research has focused on therapeutics. A combinational approach of traditional drug development and drug repurposing is necessary to make progress in treating and preventing COVID-19 in a timely manner. While developing new drugs is critical, repurposing existing molecules has been a major strategy. In the early stages…

GVN STATEMENT ON RECENT COVID-19 VACCINE DATA SUCCESS

By vgn1 | November 17, 2020

Baltimore, Maryland, USA, November 17, 2020: The Global Virus Network (GVN), , which comprises global preeminent human and animal virologists from 57 Centers of Excellence and 11 Affiliates in 33 countries, said today that the 94.5% efficacy rate of the Moderna vaccine, according to early data announced yesterday, is a significant step towards developing an effective…

Global Virus Network (GVN) and the University of South Florida Launch Online Course “Microbiomes and Their Impact on Viral Infections”

By vgn1 | November 17, 2020

GVN Offers Four Scholarships to Self-Paced Online Training Course Baltimore, Maryland, USA, November 17, 2020: The Global Virus Network (GVN), together with the University of South Florida (USF) Institute on Microbiomes, recently launched the self-paced online course “Microbiomes and Their Impact on Viral Infections.” Taught by world-renowned instructors, this course will provide students, academics, and…

Rapid and Frequent Testing for COVID-19

By vgn1 | November 16, 2020

The cases of new SARS-CoV-2 infections are currently increasing at an alarming rate, suggesting that winter might bring a large healthcare crisis. Diagnostics have become a critical tool in curbing COVID-19. It is important that accurate results be obtained rapidly and that collection of samples be as fast, simple, and convenient as possible. What tests…

GVN Statement on Pfizer and BioNTech Data from COVID-19 Vaccine Study

By vgn1 | November 9, 2020

Baltimore, Maryland, USA, July 23, 2020:  The Global Virus Network (GVN), a coalition comprised of the world’s preeminent human and animal virologists from 57 Centers of Excellence and 10 Affiliates in 33 countries, said today that the results of the Phase 3 study by Pfizer and BioNTech on their mRNA-based vaccine candidate, BNT162b2, represents a…

Herd Immunity – Can We Get There?

By vgn1 | November 3, 2020

The concept of herd immunity is frequently brought up as an alternative to lockdown and intervention-based strategies for curbing the COVID-19 pandemic, this sensitive issue being much influenced by policy makers. In this context it is important to first define herd immunity. This is obtained when enough of the population has immunity to an infectious…